In Brief: Genzyme/IG Labs
This article was originally published in The Gray Sheet
Genzyme/IG Labs: Enter agreement in principle under which Genzyme would acquire all publicly held shares of genetic testing services company IG Labs in a tax-free merger worth approximately $21 mil. According to terms of the proposed deal, public stockholders of IG Labs would receive $7 in Genzyme General Division common stock for each IG Labs share. Genzyme's General Division consists of therapeutics, diagnostic products and services, pharmaceuticals and fine chemicals...
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.